Flibanserin

Common card · No. 283615

Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication attempts to improve sexual desire, increase the number of satisfying sexual events, and decrease the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth. Development by Boehringer Ingelheim was halted in October 2010, following a negative evaluation by the US Food and Drug Administration (FDA). The rights to the drug were then transferred to Sprout Pharmaceuticals, which achieved approval of the drug by the US FDA in August 2015. Addyi is approved for medical use in the United States for premenopausal women with hypoactive sexual desire disorder and in Canada for premenopausal and postmenopausal women with hypoactive sexual desire disorder. Hypoactive sexual desire disorder was recognized as a distinct...

Read on Wikipedia · Image Vaccinationist, Public domain